Influenza Update

October 19, 2017
Overview

• Update on influenza-like-illness (ILI)

• Update on IHS influenza vaccine coverage

• 2017 – 2018 NSSC vaccine and antiviral supply
U.S. Influenza Activity
Week 40 – 10/07/17

• Influenza activity was low in the U.S.

• The most frequently identified influenza virus type reported by public health laboratories during week 40 was influenza A
  • The percentage of respiratory specimens testing positive for influenza in clinical laboratories is low

• No influenza-associated pediatric deaths were reported

• The proportion of outpatient visits for influenza-like illness (ILI) was 1.4%, which is below the national baseline of 2.2%
FluView

A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2017-2018 and Selected Previous Seasons

Week

% of Visits for ILI

2017-18 season
2016-17 season
2015-16 Season
2011-12 season
2009-10 season
National Baseline
Weekly Influenza Activity Estimates Reported by State & Territorial Epidemiologists*
Week ending October 7, 2017 - Week 40

* This map indicates geographic spread & does not measure the severity of influenza activity.
Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System

Data through the week ending September 23, 2017, as of October 12, 2017
U.S. Influenza Vaccine Supply

- Influenza vaccine supply:
  - Projected: 151 to 166 million doses

- Distributed doses as of October 06, 2017
  ~ 117.2 million doses
IHS Influenza Awareness System as of 10/07/2017 (Week 40)

• Influenza-like-illness (ILI) activity in IHS is low and is at 0.6%, below the IHS baseline of 1.77%

• Only two IHS regions are reporting elevated ILI activity

• IHS has administered over 55,000 doses of influenza vaccine

• Weekly IIAS reports available on the IHS Flu Website
  • www.ihs.gov/flu
IHS ILI Activity as of 10/07/17

% of outpatient visits for influenza-like-illness (ILI)
All IHS Areas
Influenza-Like Illness (ILI) for All Surveillance Years
Percentage of Visits for ILI per week
01/04/09 to 10/07/17
IHS Influenza Vaccine Coverage

Week 40
<table>
<thead>
<tr>
<th>Age Group</th>
<th>Active Clinical Population**</th>
<th>Seasonal Flu Vaccine (At Least 1 Dose)***</th>
<th>% Seasonal Flu (At Least 1 Dose)</th>
<th>Total # Doses Administered****</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 5 months</td>
<td>5,172</td>
<td>7</td>
<td>0.1</td>
<td>7</td>
</tr>
<tr>
<td>6 - 23 months</td>
<td>28,111</td>
<td>1,532</td>
<td>5.4</td>
<td>1,540</td>
</tr>
<tr>
<td>2 - 4 years</td>
<td>72,774</td>
<td>2,185</td>
<td>3.0</td>
<td>2,191</td>
</tr>
<tr>
<td>5 - 17 years</td>
<td>269,180</td>
<td>7,709</td>
<td>2.9</td>
<td>7,740</td>
</tr>
<tr>
<td>18 - 49 years</td>
<td>554,588</td>
<td>18,416</td>
<td>3.3</td>
<td>18,497</td>
</tr>
<tr>
<td>50 - 64 years</td>
<td>231,649</td>
<td>14,211</td>
<td>6.1</td>
<td>14,254</td>
</tr>
<tr>
<td>65 + years</td>
<td>134,648</td>
<td>11,493</td>
<td>8.5</td>
<td>11,588</td>
</tr>
<tr>
<td>Children (6 months-17 years)</td>
<td>370,065</td>
<td>11,426</td>
<td>3.1</td>
<td>11,471</td>
</tr>
<tr>
<td>Adults (18 + years)</td>
<td>920,885</td>
<td>44,120</td>
<td>4.8</td>
<td>44,339</td>
</tr>
<tr>
<td>All (6 months +)</td>
<td>1,290,950</td>
<td>55,546</td>
<td>4.3</td>
<td>55,810</td>
</tr>
</tbody>
</table>

* Limited to sites that exported both doses administered and active clinical population data.
** Active Clinical is defined as patients who have had at least 2 visits in the last 3 years.
*** Number of unique patients with at least 1 dose.
**** Total # Doses Administered = All doses administered to patients including doses not included in coverage calculation due to lack of Active Clinical Population data.
Influenza Vaccine Coverage as of 10/07/2017

- Adults (18+ years)
- All (6 months +)
- Children (6 months-17 years)
Influenza Vaccine Coverage
All (6 months and over)
2016-2017 vs. 2017-2018
### Influenza Vaccine Doses Administered by Influenza Vaccine Type*

<table>
<thead>
<tr>
<th>Area</th>
<th>INACTIVE CVX CODES*</th>
<th>CVX 88 FLU-NOS**</th>
<th>CVX 135 FLU-HIGH</th>
<th>CVX 140 FLU-LIVE</th>
<th>CVX 141 FLU-LIVE3p f</th>
<th>CVX 149 FLU-LIVE4</th>
<th>CVX 150 FLU-LIVE4pf</th>
<th>CVX 155 FLU-LIVEV4</th>
<th>CVX 158 FLU-LIVE4pf ped</th>
<th>CVX 161 FLU-LIVE4p f ped</th>
<th>CVX 166 FLU-DERM4</th>
<th>CVX 168 FLU-LIVEV3ad</th>
<th>CVX 171 FLU-LIVEV3ad</th>
<th>CVX 185 FLU-RIV4</th>
<th>CVX 186 FLU-RIV4</th>
<th>Proc 99.52 Vac Inf</th>
<th>ICD-9 V04.81 Vac Inf</th>
<th>CPT Billing Codes+</th>
<th>Cumulative # of Doses Seasonal Flu</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKA</td>
<td>0</td>
<td>5</td>
<td>80</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>1259</td>
<td>0</td>
<td>409</td>
<td>74</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ALB</td>
<td>0</td>
<td>10</td>
<td>481</td>
<td>1</td>
<td>93</td>
<td>0</td>
<td>1800</td>
<td>0</td>
<td>1581</td>
<td>86</td>
<td>122</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>4187</td>
</tr>
<tr>
<td>BEM</td>
<td>0</td>
<td>3</td>
<td>112</td>
<td>1</td>
<td>15</td>
<td>0</td>
<td>975</td>
<td>1</td>
<td>770</td>
<td>44</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13</td>
<td>1934</td>
</tr>
<tr>
<td>BIL</td>
<td>0</td>
<td>4</td>
<td>397</td>
<td>0</td>
<td>27</td>
<td>0</td>
<td>1611</td>
<td>1</td>
<td>404</td>
<td>21</td>
<td>7</td>
<td>0</td>
<td>58</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>70</td>
<td>2600</td>
</tr>
<tr>
<td>CAO</td>
<td>0</td>
<td>230</td>
<td>460</td>
<td>6</td>
<td>235</td>
<td>0</td>
<td>1713</td>
<td>0</td>
<td>982</td>
<td>32</td>
<td>16</td>
<td>0</td>
<td>270</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>43</td>
<td>3987</td>
</tr>
<tr>
<td>GPA</td>
<td>0</td>
<td>29</td>
<td>599</td>
<td>1</td>
<td>141</td>
<td>0</td>
<td>3922</td>
<td>1</td>
<td>1948</td>
<td>285</td>
<td>1</td>
<td>0</td>
<td>48</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>6989</td>
</tr>
<tr>
<td>NSA</td>
<td>0</td>
<td>12</td>
<td>115</td>
<td>8</td>
<td>51</td>
<td>0</td>
<td>471</td>
<td>1</td>
<td>1518</td>
<td>49</td>
<td>58</td>
<td>0</td>
<td>48</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>26</td>
<td>2357</td>
</tr>
<tr>
<td>NAV</td>
<td>0</td>
<td>19</td>
<td>636</td>
<td>1</td>
<td>179</td>
<td>0</td>
<td>4161</td>
<td>0</td>
<td>8836</td>
<td>270</td>
<td>31</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>45</td>
<td>14179</td>
</tr>
<tr>
<td>OKC</td>
<td>1</td>
<td>81</td>
<td>796</td>
<td>1</td>
<td>107</td>
<td>0</td>
<td>1473</td>
<td>2</td>
<td>2431</td>
<td>91</td>
<td>176</td>
<td>0</td>
<td>80</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>5249</td>
</tr>
<tr>
<td>PHX</td>
<td>0</td>
<td>56</td>
<td>619</td>
<td>0</td>
<td>143</td>
<td>0</td>
<td>3821</td>
<td>0</td>
<td>2464</td>
<td>135</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>73</td>
<td>7276</td>
</tr>
<tr>
<td>POR</td>
<td>0</td>
<td>21</td>
<td>373</td>
<td>49</td>
<td>79</td>
<td>0</td>
<td>1506</td>
<td>1</td>
<td>1807</td>
<td>84</td>
<td>123</td>
<td>0</td>
<td>182</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>37</td>
<td>4262</td>
</tr>
<tr>
<td>TUC</td>
<td>0</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>959</td>
<td>0</td>
<td>30</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1002</td>
</tr>
</tbody>
</table>

### Notes

* Inactive CVX Codes 15 (FLU-TIVhx), 16 (FLU-WHOLE), 111 (FLU-LAIV3), 123 (FLU-H5N1), 144 (FLU-DERMAL), 153 (FLU-NasNOS), and 160 (H5N1,adj) should not be used to document flu vaccines given this flu season.

** CVX Code 88 (FLU-NOS) should only be used to document flu vaccines given elsewhere when flu vaccine type is unknown.

+ CPT Flu codes include: 90654-90658, 90662, 90672, 90673, 90685, 90686, G0008, and G8108.

^ ICD9 codes V04.8 and V06.6 are not displayed on this report and are not used in any of the influenza vaccine coverage calculations.
Summary

• Influenza season has started
• IHS has administered over 55,000 doses of influenza vaccine
• Weekly IIAS reports available on the IHS Flu Website
  • www.ihs.gov/flu
2017-2018
Seasonal Influenza Vaccine and Antiviral Procurement

IHS National Supply Service Center
Pharmacy Support Branch
CDR James J. Cummings, PharmD
James.Cummings@ihs.gov
## 2017-2018 Delivery Timelines

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Delivery timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Afluria® MDVs</strong></td>
<td>Multi-Dose Vial (MDV) -10 doses/vial Peds/Adult by Seqirus</td>
<td>50% by Sept. 15th, rest by Oct. 15th</td>
</tr>
<tr>
<td><strong>Fluzone® 6-35 months</strong></td>
<td>PFS - 0.25mL - 10 doses/package Pediatric (6-35 months) by Sanofi</td>
<td>40% by Aug. 15th, rest by Nov. 11th</td>
</tr>
<tr>
<td><strong>Fluarix® 3 years &amp; older</strong></td>
<td>PFS – 0.5mL – 10 doses/package Peds/Adult (3 years &amp; older) by GSK</td>
<td>50% by Sept. 15th, rest by Oct. 15th</td>
</tr>
<tr>
<td><strong>Fluzone® High Dose</strong></td>
<td>PFS – High Dose - 10 doses/package by Sanofi</td>
<td>50% by Sept. 15th, rest by Oct. 15th</td>
</tr>
<tr>
<td><strong>Other Vaccines</strong></td>
<td>Vaccines not under a delivery contract</td>
<td></td>
</tr>
</tbody>
</table>
Flu Vaccine Ordering
Post-Solicitation

• Contact “Gabe” Wyatt  aaron.wyatt@ihs.gov
  • He will forward a Flu 413 Form for ordering

• Submit Seasonal Flu Form 413 to NSSC
  • NSSC may have stock of additional contract vaccine
    ▪ If not NSSC will contact manufacturers to obtain and if authorized, will purchase additional vaccine. If contract vaccine not available NSSC will contact additional vendors to find best price

• Occasionally, FSS priced vaccine available through McKesson but no guarantees
Antiviral Ordering & Procurement

- **Tamiflu® 75mg Capsules** may purchase from NSSC at substantially reduced prices by contacting “Gabe” Wyatt ([Aaron.Wyatt@ihs.gov](mailto:Aaron.Wyatt@ihs.gov)) and he will forward a 413 form.

- **Sign & Complete 413** and fax to “Gabe” (405)951-6054 or e-mail. E-mail works much better 🌟

- Other dosage forms & strengths available thru McKesson
- NOT Reimbursable thru Insurance (POS)
- Relenza® available thru McKesson Connect
Influenza Antiviral

• Tamiflu® Capsules, 75mg, BT/10 priced at $19.24 per bottle – Expires June 2019 (part of the Shelf Life Extension Program (SLEP) for on hand Please contact NSSC for purchasing

NSSC can ship overnight delivery if needed the next day. Typically, we ship 2-3 day ground.